Cita APA

Fradet, Y., Bellmunt Molins, J., & Bajorin, D. F. (2019). Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up.

Citación estilo Chicago

Fradet, Yves, Joaquim Bellmunt Molins, y Dean F. Bajorin. Randomized Phase III KEYNOTE-045 Trial of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent Advanced Urothelial Cancer: Results of >2 Years of Follow-up. 2019.

Cita MLA

Fradet, Yves, Joaquim Bellmunt Molins, y Dean F. Bajorin. Randomized Phase III KEYNOTE-045 Trial of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine in Recurrent Advanced Urothelial Cancer: Results of >2 Years of Follow-up. 2019.